Moloney Securities Asset Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 10.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,608 shares of the biopharmaceutical company’s stock after acquiring an additional 2,632 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Pfizer were worth $1,239,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Claraphi Advisory Network LLC raised its holdings in Pfizer by 7.8% in the second quarter. Claraphi Advisory Network LLC now owns 13,330 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 967 shares in the last quarter. Lake Street Financial LLC boosted its position in shares of Pfizer by 34.4% in the second quarter. Lake Street Financial LLC now owns 34,140 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 8,737 shares during the period. Connecticut Wealth Management LLC acquired a new stake in shares of Pfizer in the second quarter worth $251,000. Reik & CO. LLC boosted its position in shares of Pfizer by 3.8% in the second quarter. Reik & CO. LLC now owns 18,895 shares of the biopharmaceutical company’s stock worth $819,000 after buying an additional 690 shares during the period. Finally, SG Americas Securities LLC boosted its position in Pfizer by 684.1% during the second quarter. SG Americas Securities LLC now owns 926,405 shares of the biopharmaceutical company’s stock valued at $40,132,000 after purchasing an additional 808,260 shares during the last quarter. 71.81% of the stock is owned by institutional investors.

PFE stock traded up $0.25 during trading on Tuesday, reaching $35.64. 595,709 shares of the stock were exchanged, compared to its average volume of 30,291,382. Pfizer Inc. has a twelve month low of $35.86 and a twelve month high of $46.47. The firm has a market capitalization of $202.10 billion, a P/E ratio of 11.90, a P/E/G ratio of 2.90 and a beta of 0.63. The business’s 50 day simple moving average is $41.55. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.

Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The business had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business earned $0.77 earnings per share. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 4.04%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

PFE has been the topic of several recent research reports. Barclays restated a “hold” rating and set a $41.00 target price on shares of Pfizer in a report on Thursday, May 9th. Morgan Stanley lowered Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. Finally, UBS Group reiterated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Fourteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $46.56.

In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Frank A. Damelio sold 153,184 shares of Pfizer stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares in the company, valued at $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is the return on assets formula?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.